Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
Milica Perosevic,1,2 Nicholas A Tritos1,3 1Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA; 2Department of Medicine, South Shore Hospital, South Weymouth, MA, USA; 3Harvard Medical School, Boston, MA, USACorrespondence: Nicholas A Tritos, Massachusetts General Hospital, Neuroend...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-utility-of-osilodrostat-in-cushings-disease-review-of-current-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1797838078639865856 |
|---|---|
| author | Perosevic M Tritos NA |
| author_facet | Perosevic M Tritos NA |
| author_sort | Perosevic M |
| collection | DOAJ |
| description | Milica Perosevic,1,2 Nicholas A Tritos1,3 1Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA; 2Department of Medicine, South Shore Hospital, South Weymouth, MA, USA; 3Harvard Medical School, Boston, MA, USACorrespondence: Nicholas A Tritos, Massachusetts General Hospital, Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, 100 Blossom Street, Suite #140, Boston, MA, 02114, USA, Tel +1 617 726 7948, Fax + 1 617 726 1241, Email ntritos@mgh.harvard.eduAbstract: Cushing’s disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pituitary neurosurgeon. Hypercortisolism may often persist or recur after initial surgery. Patients with persistent or recurrent CD will generally benefit from medical therapy, often administered to patients who underwent radiation therapy to the sella and are awaiting its salutary effects. There are three groups of medications directed against CD, including pituitary-targeted medications that inhibit ACTH secretion from tumorous corticotroph cells, adrenally-directed medications that inhibit adrenal steroidogenesis and a glucocorticoid receptor (GR) antagonist. The focus of this review is osilodrostat, a steroidogenesis inhibitor. Osilodrostat (LCI699) was initially developed to lower serum aldosterone levels and control hypertension. However, it was soon realized that osilodrostat also inhibits 11-beta hydroxylase (CYP11B1), leading to a reduction in serum cortisol levels. The focus of drug development then shifted from treatment of hypertension to treatment of hypercortisolism in CD. In a series of studies (LINC 1 through 4), osilodrostat was shown to be effective in normalizing 24-h urinary free cortisol (UFC) in the majority of treated patients and was approved for patients with CD who have failed surgery or are not surgical candidates. Further study is needed to examine the role of combination therapy as well as long-term outcomes of treated patients. Osilodrostat was shown to have an overall good safety profile. Most common adverse effects include nausea, headache, fatigue, arthralgias, dizziness, prolonged QTc interval, hypokalemia. In females, the drug can cause hirsutism and acne. Osilodrostat is administered twice daily, making it a good choice for patients with difficulty adhering to more complex regimens. Osilodrostat has an important, albeit adjunctive, role in the management of patients with CD.Keywords: Cushing’s disease, Cushing’s syndrome, osilodrostat, LCI699, pituitary adenoma, steroidogenesis inhibitor, medical therapy |
| first_indexed | 2024-04-09T15:36:07Z |
| format | Article |
| id | doaj.art-fd7835679150489eb07f0e39a812001c |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-09T15:36:07Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-fd7835679150489eb07f0e39a812001c2023-04-27T19:02:47ZengDove Medical PressDrug Design, Development and Therapy1177-88812023-04-01Volume 171303131283345Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available LiteraturePerosevic MTritos NAMilica Perosevic,1,2 Nicholas A Tritos1,3 1Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA; 2Department of Medicine, South Shore Hospital, South Weymouth, MA, USA; 3Harvard Medical School, Boston, MA, USACorrespondence: Nicholas A Tritos, Massachusetts General Hospital, Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, 100 Blossom Street, Suite #140, Boston, MA, 02114, USA, Tel +1 617 726 7948, Fax + 1 617 726 1241, Email ntritos@mgh.harvard.eduAbstract: Cushing’s disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pituitary neurosurgeon. Hypercortisolism may often persist or recur after initial surgery. Patients with persistent or recurrent CD will generally benefit from medical therapy, often administered to patients who underwent radiation therapy to the sella and are awaiting its salutary effects. There are three groups of medications directed against CD, including pituitary-targeted medications that inhibit ACTH secretion from tumorous corticotroph cells, adrenally-directed medications that inhibit adrenal steroidogenesis and a glucocorticoid receptor (GR) antagonist. The focus of this review is osilodrostat, a steroidogenesis inhibitor. Osilodrostat (LCI699) was initially developed to lower serum aldosterone levels and control hypertension. However, it was soon realized that osilodrostat also inhibits 11-beta hydroxylase (CYP11B1), leading to a reduction in serum cortisol levels. The focus of drug development then shifted from treatment of hypertension to treatment of hypercortisolism in CD. In a series of studies (LINC 1 through 4), osilodrostat was shown to be effective in normalizing 24-h urinary free cortisol (UFC) in the majority of treated patients and was approved for patients with CD who have failed surgery or are not surgical candidates. Further study is needed to examine the role of combination therapy as well as long-term outcomes of treated patients. Osilodrostat was shown to have an overall good safety profile. Most common adverse effects include nausea, headache, fatigue, arthralgias, dizziness, prolonged QTc interval, hypokalemia. In females, the drug can cause hirsutism and acne. Osilodrostat is administered twice daily, making it a good choice for patients with difficulty adhering to more complex regimens. Osilodrostat has an important, albeit adjunctive, role in the management of patients with CD.Keywords: Cushing’s disease, Cushing’s syndrome, osilodrostat, LCI699, pituitary adenoma, steroidogenesis inhibitor, medical therapyhttps://www.dovepress.com/clinical-utility-of-osilodrostat-in-cushings-disease-review-of-current-peer-reviewed-fulltext-article-DDDTcushing’s diseasecushing’s syndromeosilodrostatlci699pituitary adenomasteroidogenesis inhibitormedical therapy |
| spellingShingle | Perosevic M Tritos NA Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature Drug Design, Development and Therapy cushing’s disease cushing’s syndrome osilodrostat lci699 pituitary adenoma steroidogenesis inhibitor medical therapy |
| title | Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature |
| title_full | Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature |
| title_fullStr | Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature |
| title_full_unstemmed | Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature |
| title_short | Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature |
| title_sort | clinical utility of osilodrostat in cushing rsquo s disease review of currently available literature |
| topic | cushing’s disease cushing’s syndrome osilodrostat lci699 pituitary adenoma steroidogenesis inhibitor medical therapy |
| url | https://www.dovepress.com/clinical-utility-of-osilodrostat-in-cushings-disease-review-of-current-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT perosevicm clinicalutilityofosilodrostatincushingrsquosdiseasereviewofcurrentlyavailableliterature AT tritosna clinicalutilityofosilodrostatincushingrsquosdiseasereviewofcurrentlyavailableliterature |